Page History
...
- Where do you show that this challenge assay is done against M. Tuberculosis (or any microbe of interest, like SARS-CoV-2)? - use NHOID? NHOID is not appropriate here because in this case the subject of study is not the TB bug itself but whether someone has been previously exposed with TB. A positive result does not mean the person is currently infected with TB, it may mean the person had been previously infected or vaccinated with TB. NHOID is used when you know the bug or reference strain is presented in the testing sample.
Status colour Green CP domain has developed a new standard variable called Test Condition Agent/CNDAGT (CP Specification), which is used to represent stimulating agents, like the values in ASSYAG above, should this variable be added to LB, or IS?title Team agrees Status colour Green title Team agrees - Lastly, Interferon-Gamma Response Assay is a classic immunological test, is it correct to map this to the LB domain?
- Can we model this in the IS domain, see example dataset below. Yes -
Status colour Green title Team Agrees - If we model this test in IS, how do we distinguish it from the INFg test in lab. Can we draw the line where if we are running a routine lab test looking for IFNg levels it goes to LB vs. IFNg challenge/response test toward a specific, known microorganism then it goes to IS? Yes-
Status colour Green title Team Agrees
- Can we model this in the IS domain, see example dataset below. Yes -
...
Dataset wrap | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
...
Overview
Content Tools